Yoseph Shaaltiel, Executive VP, R&D at Protalix BioTherapeutics, Inc. (PLX), sold 53,027 shares at $7.00 ($371K) on 2010-08-05, disclosed to the SEC on 2010-08-09.
Scheduled sale ($371k) by Executive VP, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.00 | 48,408 | $339K | 91.3% |
| 2 | $7.00 | 4,619 | $32K | 8.7% |
| Total | $7.00 avg | 53,027 | $371K | 100% |
| Filing → |
| PLX | SELL | 2010-05-03 | $89K | — | Filing → |
| PLX | SELL | 2010-04-16 | $9K | — | Filing → |
| PLX | SELL | 2010-03-25 | $2.7M | — | Filing → |